CA
CORT icon

CoreCap Advisors’s Corcept Therapeutics CORT Stock Holding History

CoreCap Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-73
Closed -$2.94K – 3195
2026
Q1 		$2.94K Hold
73
– – ﹤0.01% 2312
2025
Q4 		$2.54K Hold
73
– – ﹤0.01% 2410
2025
Q3 		$6.07K Sell
73
-8,737
-99% -$632K ﹤0.01% 2122
2025
Q2 		$647K Sell
8,810
-3,730
-30% -$270K 0.03% 454
2025
Q1 		$1.43M Buy
12,540
+12,429
+11,197% +$757K 0.06% 264
2024
Q4 		$5.59K Hold
111
– – ﹤0.01% 1953
2024
Q3 		$5.14K Buy
+111
New +$3.94K ﹤0.01% 1969
2024
Q2 		– Sell
-2,756
Closed -$69.4K – 1802
2024
Q1 		$69.4K Buy
+2,756
New +$65.1K ﹤0.01% 987
2022
Q4 		$138K Buy
+6,780
New +$170K 0.01% 622

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CoreCap Advisors's CORT Position: Q2 2026 in Review

CoreCap Advisors sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 73 shares — an estimated $2.94K sold.

CoreCap Advisors first reported a position in CORT in Q4 2022 and held it in 9 quarters. The position peaked at $1.43M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • CoreCap Advisors reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • CoreCap Advisors sold 73 Corcept Therapeutics shares in Q2 2026, an estimated $2.94K.
  • CoreCap Advisors first reported a position in Corcept Therapeutics in Q4 2022 and held it in 9 quarters.
  • CoreCap Advisors's Corcept Therapeutics position peaked at $1.43M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.